MarketMoodz
BioMarin's VOXZOGO Hits Primary Endpoint; Stock Jumps
BioMarin said positive Phase 3 CANOPY-HCH-3 results for VOXZOGO (vosoritide) in children with hypochondroplasia showed a statistically significant improvement in annualized growth velocity, and shares climbed roughly 8% on the news. The company plans a supplemental NDA submission in Q3 2026, a potential regulatory catalyst for expanding VOXZOGO beyond achondroplasia.
Key Takeaways
- CANOPY-HCH-3 reportedly met its primary endpoint with a statistically significant increase in annualized growth velocity versus placebo.
- At week 52, VOXZOGO produced a reported 2.33 cm/year increase in annualized growth velocity and showed significant arm‑span gains (p=0.004).
- BioMarin plans a supplemental NDA submission to the FDA in Q3 2026 for hypochondroplasia.
- Shares rose about 8% to roughly $54.24–$54.27 after the data release, while analyst targets average $87.47 (range: $50–$80).
- The claim is based on secondary reporting and awaits primary data release and formal FDA review.
People Involved
- Greg FribergEVP and Chief R&D Officer, BioMarin
Entities Involved
- BioMarin Pharmaceutical Inc. (BMRN)Developer of VOXZOGO (vosoritide) and sponsor of the CANOPY‑HCH‑3 trial
- VOXZOGO (vosoritide)Investigational/approved therapy for growth‑velocity disorders; candidate for hypochondroplasia label expansion
- U.S. Food and Drug Administration (FDA)Regulatory reviewer for the planned supplemental NDA
- BofA SecuritiesAnalyst firm; cited $80 price target
- CitigroupAnalyst firm; cited $75 price target
- HC Wainwright & Co.Analyst firm; cited $50 price target and Neutral rating
MarketMoodz Analysis
For investors, the CANOPY‑HCH‑3 readout — if confirmed by primary data — materially broadens VOXZOGO’s commercial runway beyond achondroplasia. A 2.33 cm/year improvement in annualized growth velocity and a significant arm‑span gain address clinically meaningful outcomes in a condition with no approved therapies, which supports a high-priced orphan drug economics even in a small patient pool. The reported Q3 2026 sNDA plan creates a clear two‑year timeline for a regulatory catalyst; that timeline and successful label expansion would likely underpin multiple valuation reratings and justify analyst optimism reflected in an average $87.47 price target.
Risks are concentrated and concrete. The report relies on secondary coverage pending release of the full trial dataset and regulatory filing, so investors should seek confirmation of endpoints, safety data, and effect durability before recalibrating positions. Even with positive efficacy, uptake depends on real‑world access, payer coverage, and physician adoption in a niche pediatric population. Watch for BioMarin’s primary data release, the formal sNDA filing and FDA acceptance decision, any safety signals in the detailed dataset, and subsequent analyst revisions to model revenue, market penetration, and pricing assumptions.
Source: Original Article